BioLineRx (NASDAQ:BLRX) Research Coverage Started at StockNews.com

StockNews.com assumed coverage on shares of BioLineRx (NASDAQ:BLRX) in a research note issued to investors on Sunday. The brokerage issued a hold rating on the biotechnology company’s stock.

Separately, HC Wainwright reaffirmed a “buy” rating and set a $21.00 price objective on shares of BioLineRx in a research report on Wednesday, November 6th.

BioLineRx Price Performance

Shares of BLRX opened at $0.28 on Friday. The stock has a market capitalization of $22.08 million, a PE ratio of -0.61 and a beta of 1.48. BioLineRx has a 1 year low of $0.25 and a 1 year high of $1.89. The company has a debt-to-equity ratio of 1.34, a quick ratio of 1.49 and a current ratio of 1.61. The company’s 50-day simple moving average is $0.48 and its 200-day simple moving average is $0.61.

Institutional Trading of BioLineRx

Large investors have recently made changes to their positions in the company. CVI Holdings LLC acquired a new position in shares of BioLineRx during the second quarter worth $462,000. PVG Asset Management Corp purchased a new stake in BioLineRx during the 2nd quarter worth about $70,000. Finally, Atria Investments Inc boosted its position in shares of BioLineRx by 27.9% during the 3rd quarter. Atria Investments Inc now owns 133,974 shares of the biotechnology company’s stock worth $72,000 after acquiring an additional 29,193 shares in the last quarter. 1.56% of the stock is currently owned by hedge funds and other institutional investors.

BioLineRx Company Profile

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma.